Effect of drugs combined with cognitive behavior therapy for recurrent depressive disorder
SU Jin-ge1 JIANG Hai-jun2 LIU Xiao-mei
1. Department of Psychiatry, Huizhou Second People′s Hospital, Guangdong Province, Huizhou 516100, China;
2. Department of Psychiatry, Huizhou Demobilized Veterans Hospital, Guangdong Province, Huizhou 516100, China
Abstract：Objective To observe the effect of drugs combined with cognitive behavior therapy for recurrent depressive disorder. Methods From June 2019 to September 2020, 100 patients with recurrent depressive disorder in Huizhou Second People′s Hospital and Huizhou Demobilized Veterans Hospital were selected, and they were divided into two groups according to the admission time, 50 cases in each group. The control group was given drug treatment, and the study group was given drug combined with cognitive behavior therapy. The Hamilton depression scale (HAMD), selfrating depression scale (SDS) and the MOS item short from health survey (SF-36) scores before and after treatment and incidence of adverse reactions were compared and analyzed between the two groups. Results There was no significant difference in HAMD score between the two groups before treatment (P>0.05). At 4 and 8 weeks of treatment, the HAMD scores of the two groups were lower than those before treatment, and those in the study group were lower than those in the control group, the differences were statistically significant (P<0.05). There was no significant difference in SDS score between the two groups before treatment (P>0.05). At 4 and 8 weeks of treatment, the SDS scores of the two groups were lower than those before treatment, and those in the study group were lower than those in the control group,the differences were statistically significant (P<0.05). There was no significant difference in SF-36 score between the two groups before treatment (P>0.05). At 4 and 8 weeks of treatment, the SF-36 scores of the two groups were higher than those before treatment, and those in the study group were higher than those in the control group, the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions such as headache, constipation, nausea, tachycardia, dry mouth, drowsiness, increase in appetite, and weight gain between the two groups (P>0.05). Conclusion For patients with recurrent depressive disorder, drugs combined with cognitive behavioral therapy can effectively improve clinical symptoms, with high security, and the clinical value is remarkable.
京公网安备 11010502046607号